Search
forLearn
5 / 34 resultslearn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
learn Metformin
diabetes drug with anti-inflammatory, immunomodulatory, and insulin-sensitizing properties
learn Verteporfin
chemical that might completely regrow follicles from hair transplant extractions
learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
Research
5 / 1000+ resultsresearch Nonsteroidal Tissue Selective Androgen Receptor Modulators: A Promising Class of Clinical Candidates
Selective androgen receptor modulators (SARMs) are a promising type of drug for various health conditions due to their targeted actions.
research Small Molecule Agents Against Alopecia: Potential Targets And Related Pathways
New small molecule drugs could help treat hair loss.
research Design, Synthesis, and Preclinical Evaluation of Prostate-Specific Membrane Antigen Targeted 99mTc-Radioimaging Agents
Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.
research Sulfatase Inhibitors: A Patent Review
The document concludes that research on sulfatase inhibitors should continue due to their potential in treating various diseases, despite some clinical trial failures.
research Inhibition of Rat Alpha-Reductases by Finasteride: Evidence for Isozyme Differences in the Mechanism of Inhibition
Finasteride effectively blocks rat enzymes, but with varying methods and strength.
Community Join
5 / 1000+ resultscommunity Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia
Kintor Pharma completed enrolling subjects for a Phase III trial of KX-826 for male hair loss treatment. The trial includes a 24-week treatment period and a 4-week safety follow-up, with results expected in about 6-7 months.
community Every Single RU58841 Study Analysed - Youtube Video
RU58841 is discussed as a potential hair loss treatment, with comparisons to finasteride. There is interest in leaked trial data, but no official clinical validation or approval for RU58841.
community New company Amplifica gets $11.8 million in financing for development of its hair loss products. Dr. Maksim Plikus and William Rassman are co-founders.
New company Amplifica receives $11.8 million for hair loss product development, co-founded by Dr. Maksim Plikus and William Rassman. Users discuss undisclosed product candidates and application methods.
community Any news about possible cures?
Potential cures for Androgenic Alopecia, specifically Kintor/HMI 115, CosmeRNA, Minoxidil and Finasteride.
community PP405 Identity Research
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.